Changes in HAQ-DI and HAQ-PS analyzed by subsets of sex, disease duration, type of anti-TNF, baseline HAQ-DI, and baseline HAQ-PS.
| N | Δ HAQ-DI Year 1 | Δ HAQ-PS Year 1 | N | Δ HAQ-DI Year 3 | Δ HAQ-PS Year 3 | |
|---|---|---|---|---|---|---|
| All | 249 | −0.27 (0.04) | −0.54 (0.07) | 96 | −0.25 (0.07) | −0.55 (0.11) |
| Sex | ||||||
| Female | 176 | −0.26 (0.05) | −0.48 (0.08) | 68 | −0.32 (0.08) | −0.50 (0.13) |
| Male | 73 | −0.30 (0.07) | −0.71 (0.10) | 28 | −0.22 (0.16) | −0.65 (0.21) |
| p | 0.6763 | 0.1137 | 0.5413 | 0.5610 | ||
| Age, yrs | ||||||
| < 45 | 72 | −0.29 (0.07) | −0.57 (0.10) | 26 | −0.13 (0.15) | −0.65 (0.48) |
| 46–55 | 63 | −0.23 (0.08) | −0.47 (0.12) | 25 | −0.27 (0.14) | −0.46 (0.20) |
| 56–65 | 63 | −0.9 (0.06) | −0.64 (0.13) | 24 | −0.17 (0.10) | −0.56 (0.25) |
| > 65 | 51 | −0.28 (0.10) | −0.47 (0.21) | 21 | −0.48 (0.19) | −1.10 (0.19) |
| p | 0.9170 | 0.8262 | 0.3486 | 0.0457 | ||
| Disease duration, yrs | ||||||
| <2 | 20 | −0.32 (0.14) | −0.55 (0.26) | 20 | −0.33 (0.13) | −0.68 (0.22) |
| 3–10 | 100 | −0.31 (0.06) | −0.40 (0.08) | 38 | −0.39 (0.16) | −0.46 (0.17) |
| 11–20 | 78 | −0.19 (0.06) | −0.50 (0.14) | 35 | −0.14 (0.12) | −0.65 (0.24) |
| > 20 | 38 | −0.29 (0.11) | −0.88 (0.15) | 23 | −0.27 (0.12) | −0.84 (0.25) |
| p | 0.5686 | 0.1148 | 0.5176 | 0.2818 | ||
| Anti-TNF drug | ||||||
| Adalimumab | 30 | −0.29 (0.12) | −0.75 (0.20) | −−* | −−* | |
| Etanercept | 202 | −0.28 (0.04) | −0.53 (0.07) | |||
| Infliximab | 17 | −0.15 (0.08) | −0.34 (0.21) | |||
| p | 0.6481 | 0.2915 | ||||
| Baseline HAQ-DI | ||||||
| < 0.5 | 29 | 0.00 (0.05) | −0.61 (0.17) | 8 | 0.09 (0.10) | −0.35 (0.14) |
| 0.6–1.0 | 55 | −0.13 (0.07) | −0.62 (0.11) | 21 | 0.16 (0.13) | −0.34 (0.24) |
| 1.1–1.5 | 73 | −0.21 (0.07) | −0.28 (0.16) | 30 | −0.30 (0.10) | −0.46 (0.17) |
| 1.6–2.0 | 48 | −0.37 (0.08) | −0.53 (0.16) | 20 | −0.28 (0.12) | −0.36 (0.31) |
| > 2.0 | 44 | −0.63 (0.12) | −0.79 (0.13) | 17 | −0.81 (0.25) | −1.1 (0.28) |
| p | < 0.001 | 0.0753 | 0.0330 | 0.1166 | ||
| Baseline HAQ-PS | ||||||
| < 1.0 | 31 | −0.07 (0.08) | 0.31 (0.21) | 18 | −0.20 (0.30) | 0.30 (0.24) |
| 1.1–1.5 | 36 | −0.25 (0.08) | −0.471 (0.12) | 27 | −0.10 (0.04) | 0.04 (0.17) |
| 1.6–2.0 | 68 | −0.19 (0.07) | −0.55 (0.10) | 19 | −0.14 (0.20) | −0.53 (0.20) |
| > 2.1 | 75 | −0.44 (0.07) | −0.94 (0.10) | 23 | −0.48 (0.10) | −1.04 (0.17) |
| p | 0.005 | < 0.0001 | 0.0842 | < 0.0001 | ||
↵* Insufficient numbers for analysis. TNF: tumor necrosis factor; HAQ-DI: Health Assessment Questionnaire Disability Index; HAQ-PS: Health Assessment Questionnaire Pain Score; RA: rheumatoid arthritis; PsA: psoriatic arthritis; AS: ankylosing spondylitis.